Public health impact of RSV vaccination among adults aged 60 years and older in the United States using real-world evidence from the initial post-introduction season

Background Respiratory syncytial virus (RSV) is an important cause of severe respiratory illness in older adults and adults with certain health conditions. Adjuvanted RSVPreF3 and non-adjuvanted RSVpreF vaccines were approved in 2023 for use in adults aged ≥60 years in the United States (US). This s...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Frederik Verelst, David Singer, Jonathan Graham, Mei Grace, Elizabeth M. La, Eliana Biundo
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Taylor & Francis Group 2025-12-01
coleção:	Expert Review of Vaccines
Assuntos:	Public health impact respiratory syncytial virus vaccination United States Markov model
Acesso em linha:	https://www.tandfonline.com/doi/10.1080/14760584.2025.2539893
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!